An AI data platform company for skin health · an end-to-end AI-powered skin problem solver.
Houyi Biopharmaceuticals (Hangzhou) Co., Ltd. is a wholly-owned subsidiary of Zhejiang Kuafu Biopharmaceuticals. Positioned as an AI data platform company in skin health, Houyi delivers an AI-powered end-to-end technical service covering skin health data capture and management, intelligent diagnosis, testing and evaluation, personalized regimen generation, and technology output.
Distinct from traditional paths that only offer skincare products or a single testing modality, Houyi is grounded in the mechanisms of skin microbiome–host interaction, cell-fate regulation and regenerative medicine — and powered by bioinformatics and AI modelling — building a complete data→mechanism→solution service chain that covers skincare, repair and regeneration.
Cell-level revival of skin-native health
Led by Prof. Duanqing Pei, European Academy of Sciences — collaborating with Westlake University, Shanghai Regenerative Medicine Institute, Korea LSIST, and Kuafu Biopharmaceuticals.
Chair Professor, Westlake University · Foreign Member, European Academy of Sciences · Leader, National Key R&D Program on Stem Cells
Lifetime work on cell-fate regulation and somatic reprogramming. Discoveries include vitamin C enhancing iPSC generation, MET being essential for nuclear reprogramming, and chemically induced pluripotent stem cells. National Natural Science Award (2013, 2018), European Academy of Sciences member (2025). Nature calls him a pioneer of global regenerative medicine.
Hangzhou, China · Basic Science Research
National key laboratory in incubation — source of regenerative medicine theory, covering cell reprogramming, skin stem cells and organoids.
Seoul, Korea · Raw Material & Delivery
Research on marine bio-active ingredients and transdermal delivery — discovery, purification and structural characterization of actives such as Fucoidan.
Hangzhou, China · Core Research Hub
Founded by Prof. Pei as the skin-stem-cell frontier research arm — focusing on chemically induced pluripotency (CIP), extracellular vesicles, skin organoids, and skin genomics. Hangzhou R&D center ~2,000 ㎡, 30-ton/year stem-cell production line under upgrade. Kuafu does basic research; Houyi does commercialization.
Coming soon.
Coming soon.